FDA Approves Enspryng as the First At-Home Treatment for TED

FDA has approved Genentech’s Enspryng (satralizumab-mwge) for thyroid eye disease, clearing the first treatment for the condition that a patient can inject at home rather than receive by clinic infusion. The approval, announced 15–16 October, is a label expansion for a biologic FDA first approved six years ago for an unrelated autoimmune disease — and it adds a third drug, with a different delivery model, to a treatment class that had only two options.

A third drug, a different delivery model

Thyroid eye disease is an autoimmune condition, usually linked to Graves’ disease, in which inflammation and swelling behind the eyes push the eyeballs forward (proptosis) and can cause double vision (diplopia), pain and, in severe cases, vision loss. Until this approval, patients had two FDA-cleared options: Amgen’s teprotumumab (Tepezza), approved in 2020 as the first TED-specific therapy, and Viridian’s veligrotug (Lumvoa), approved in June 2026 with a broader label covering both active and chronic disease. Both are delivered by intravenous infusion on a clinic schedule — five infusions over 12 weeks for Lumvoa, a comparable course for Tepezza.

Enspryng changes the delivery model rather than the target population. It is a humanized monoclonal antibody that blocks the interleukin-6 receptor, dosed by subcutaneous injection with maintenance doses every four weeks; after training from a healthcare provider, a patient or a caregiver can give the injection outside a clinic. Genentech’s framing of the approval leads with that distinction — the company describes Enspryng as the first and only at-home option in the class — and for RA/QA teams the operational read-through is a site-of-care shift: less reliance on infusion-center capacity and scheduling, and a label, instructions-for-use and (where applicable) patient-support program built around self-administration rather than supervised infusion.

A split trial result FDA approved on anyway

The filing rested on two placebo-controlled Phase 3 trials, SatraGO-1 and SatraGO-2, which together enrolled 258 patients across 19 countries. SatraGO-2 met its primary endpoint: a proptosis response — reduction in the forward displacement of the eye — in 52.9% of patients on Enspryng at week 24, against 23.4% on placebo, with a secondary diplopia response of roughly 61% versus 26%. SatraGO-1 tested the same primary endpoint and did not reach statistical significance, at 49% versus 31%; trade reporting on the result has attributed the miss to an unexpectedly high placebo response in that trial rather than a weaker drug effect. FDA’s decision to approve on the strength of SatraGO-2 and the combined evidence package, notwithstanding SatraGO-1’s result, is itself a data point for sponsors benchmarking what a mixed two-trial package can support in a supplemental BLA for an already-marketed biologic.

What is not yet public

Regulatory News has not seen Enspryng’s updated prescribing information for the TED indication. Genentech’s and Roche’s releases describe the trial safety profile as consistent with Enspryng’s known profile in NMOSD, where the label’s central warning concerns an increased risk of serious infection and recommends screening for hepatitis B and tuberculosis before starting treatment; neither company release nor the trade coverage reviewed for this story describes a new boxed warning or REMS specific to the TED indication, but Regulatory News has not confirmed that against the FDA-approved label itself and is not asserting an absence beyond what has been reported.

Frequently asked questions

What did FDA approve, and when?

FDA approved a supplemental Biologics License Application for Enspryng (satralizumab-mwge), from Genentech, a member of the Roche Group, adding thyroid eye disease (TED) in adults as a second approved use. Genentech's press release is dated October 15, 2026, the application's priority-review goal date; Roche's own release and the wire pickup are dated October 16.

Why does the at-home delivery matter?

Enspryng is given by subcutaneous injection, with maintenance dosing every four weeks; after training from a healthcare provider, a patient or caregiver can administer it outside a clinical setting. The two other FDA-approved TED therapies, Amgen's Tepezza (teprotumumab) and Viridian's Lumvoa (veligrotug), are both given by IV infusion on a clinic schedule. Enspryng is the first of the three a patient can take home.

What did the trials show?

The approval rests on two placebo-controlled Phase 3 trials, SatraGO-1 and SatraGO-2, enrolling 258 patients across 19 countries. SatraGO-2 met its primary endpoint: a proptosis response in 52.9% of patients on Enspryng versus 23.4% on placebo at week 24, with a diplopia response of roughly 61% versus 26%. SatraGO-1 did not reach statistical significance on the same proptosis endpoint (49% versus 31%), which trade reporting attributes to an unusually high placebo response in that trial. FDA approved on the totality of both studies.

Is this Enspryng's only pending FDA decision?

No. Enspryng was first approved in 2020 for neuromyelitis optica spectrum disorder (NMOSD) in adults who are AQP4-antibody positive; TED is its second approved indication. A separate FDA decision on a third potential indication, MOGAD (myelin oligodendrocyte glycoprotein antibody-associated disease), is expected in January 2027.